Biogen Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Biogen Inc (BIIB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Biogen Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 10,297M vs 451,491M combined for its competitors (2.2% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+8.9% annualized vs trailing 12 months), vs accelerating (+6.4%) for its tracked peer group.
- Growth: Biogen Inc generated 10.6% revenue growth year over year in Q3 2026, vs 12.8% for its competitors combined.
- Profitability: Its -0.7% net margin compares with 17.4% for the peer group.
- Scale: Biogen Inc ranks #6 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 3.8% of industry market cap.
- Peer revenue share: Biogen Inc accounted for 2.3% of combined revenue among its tracked peer group, down from 2.3% a year earlier.
- Peer differentiation: Revenue per employee of $1.37M compares with $0.98M for the peer group (1.4x).
- Structure: Biogen Inc operates in the following segments: Reportable.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
BIIB Sales vs. its Competitors, Q3 2026
Biogen Inc reported revenue growth of 10.63 % year on year in Q3 2026, below its competitors' combined revenue growth of 12.80 %.
With a net margin of -0.73 %, Biogen Inc reported lower profitability than its competitors (17.39 %).
Biogen Inc generated 2.28 % of the combined sales of its peer group, down from 2.32 % a year earlier.
API endpoints for this dataset
Biogen Inc vs. its Competitors, Q3 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Biogen Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Biogen Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Biogen Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (9) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Biogen Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.8% year over year, combined, vs 10.6% for Biogen Inc. Biogen Inc's share of combined industry revenue moved from 6.80% to 6.23%, a loss of 0.57 percentage points.
Biogen Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Biogen Inc | Yes | Yes | No | No |
| Competitors combined (130) | ||||
| High-Confidence Competitors (31) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BIIB Stock Performance relative to its Competitors
BIIB Stock Performance relative to High-Confidence Competitors
BIIB Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 4 | Revolution Medicines Inc | 282.9% | Outperformed |
| 5 | Dianthus Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Biogen Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Biogen Inc's Comment on Competition and Industry Peers
Competition in the biotechnology and pharmaceutical industries is intense and comes from many and varied sources, including specialized biotechnology firms and large pharmaceutical companies. Many of our competitors are working to develop products similar to those we are developing or already market and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. Certain of these companies have substantially greater financial, marketing and research and development resources than we do.
We believe that competition and leadership in the industry is based on managerial and technological excellence and innovation as well as establishing patent and other proprietary positions through research and development. The achievement of a leadership position also depends largely upon our ability to identify and exploit commercially the products resulting from research and the availability of adequate financial resources to fund facilities, equipment, personnel, clinical testing, manufacturing and marketing. Another key aspect of remaining competitive within the industry is recruiting and retaining qualified scientists and technicians. We believe that we have been successful in attracting skilled and experienced scientific personnel.
Competition among products approved for sale may be based, among other things, on patent position, product efficacy, safety, convenience, reliability, availability and price. In addition, early entry of a new pharmaceutical product into the market may have important advantages in gaining product acceptance and market share. Accordingly, the relative speed with which we can develop products, complete the testing and approval process and supply commercial quantities of products will have an important impact on our competitive position.
We may face increased competitive pressures as a result of the emergence of
biosimilars. In the U.S., a number of our marketed products, including AVONEX,
TYSABRI and RITUXAN, are licensed under the Public Health Service Act (PHSA)
as biological products. In March 2010, U.S. healthcare reform legislation amended
the PHSA to authorize the FDA to approve biological products, known as biosimilars
or follow-on biologics, that are shown to be highly similar to previously approved
biological products based upon potentially abbreviated data packages. The approval
pathway for biosimilars does, however, grant a biologics manufacturer a 12 year
period of exclusivity from the date of approval of its biological product before
biosimilar competition can be introduced. Biosimilars legislation has also been
in place in the E.U. since 2003. In December 2012, guidelines issued by the
EMA for approving biosimilars of marketed monoclonal antibody products became
effective. If a biosimilar version of one of our products were approved, it
could reduce our sales of that product.
Additional information about the competition that our marketed products face
is set forth below.
AVONEX, TYSABRI and TECFIDERA
Each of AVONEX, TYSABRI and TECFIDERA competes with the following products:
Along with us, a number of companies are working to develop additional treatments
for MS that may in the future compete with AVONEX, TYSABRI, TECFIDERA or all
of them. For example, a marketing application for LEMTRADA (alemtuzumab) (developed
by Sanofi) has been approved in the E.U. as a treatment for MS in September
2013. In addition, the commercialization of our own products, such as TECFIDERA,
may negatively impact future sales of AVONEX, TYSABRI or both. Further, following
the expected expiration of Teva Pharmaceutical’s patent protection for
COPAXONE (May 2014 for its U.S. patents and in May 2015 for its European patents),
we anticipate that additional companies will introduce similar versions of COPAXONE
that may also create further competition in the MS market.
FAMPYRA
FAMPYRA is indicated as a treatment to improve walking in adult patients with
MS who have walking disability and is the first treatment that addresses this
unmet medical need with demonstrated efficacy in people with all types of MS.
FAMPYRA is currently the only therapy approved to improve walking in patients
with MS, and benefits from exclusivity rights that prohibit generic versions
from being marketed.
FUMADERM
FUMADERM competes with several different types of therapies in the psoriasis
market within Germany, including oral systemics such as methotrexate and cyclosporine.
RITUXAN IN ONCOLOGY
RITUXAN competes with several different types of therapies in the oncology market,
including:
TREANDA (bendamustine HCL) (marketed by Cephalon (Teva Pharmaceuticals)), which
is indicated for CLL and for patients with indolent B-cell NHL that has progressed
within 6 months of treatment with RITUXAN.
ARZERRA (ofatumumab) (marketed by GenMab in collaboration with GlaxoSmithKline),
which is indicated for CLL patients refractory to both alemtuzumab and fludarabine.
We also expect that over time GAZYVA will compete with RITUXAN, TREANDA AND
ARZERRA in the oncology market. In addition, we are aware of other anti-CD20
molecules, including biosimilars, in development that, if successfully developed
and registered, may compete with RITUXAN and GAZYVA in the oncology market.
RITUXAN IN RHEUMATOID ARTHRITIS (RA)
RITUXAN competes with several different types of therapies in the RA market,
including:
Traditional therapies for RA, including disease-modifying anti-rheumatic drugs
such as steroids, methotrexate and cyclosporine, and pain relievers such as
acetaminophen.
TNF inhibitors, such as REMICADE (infliximab) and SIMPONI and SIMPONI ARIA (golimumab)
(marketed by Johnson & Johnson), HUMIRA (adalimumab) (marketed by AbbVie,
Inc.), ENBREL (etanercept) (marketed by Amgen, Inc. and Pfizer) and CIMZIA (certolizumab
pegol) (marketed by UCB, S.A.).
ORENCIA (abatacept) (marketed by Bristol-Myers Squibb Company).
ACTEMRA (tocilizumab) (marketed by the Roche Group).
XELJANZ (tofacitinib) (marketed by Pfizer).
We are also aware of other products, including biosimilars, in development that,
if successfully developed and registered, may compete with RITUXAN in the RA
market.
Publicly Traded Peers of Biogen Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Biogen Inc |
36,706.13 | 10,297.30 |
 Eli Lilly And Company |
1,209,663.60 | 86,462.00 |
 Johnson and Johnson |
676,352.29 | 99,335.00 |
 Abbvie Inc |
516,201.32 | 66,014.00 |
 Merck and Co Inc |
362,398.40 | 66,569.00 |
 Novartis Ag |
317,785.25 | 56,674.00 |
| SUBTOTAL | 4,697,757.89 | 739,531.41 |
Sign in to see all competitors of Biogen Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Biogen Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Biogen Inc's Competitors Named by the Company
Competitive relationships identified from Biogen Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Agentix Corp | Company report | 85% |
| Acumen Pharmaceuticals Inc | Company report | 85% |
| Filana Therapeutics Inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Larimar Therapeutics Inc | Company report | 85% |
| Jupiter Neurosciences Inc | Company report | 85% |
| Keros Therapeutics Inc | Company report | 85% |
| Redwoods Acquisition Corp | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Coya Therapeutics Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Alcon inc | Company report | 85% |
| Crispr Therapeutics Ag | Company report | 85% |
| Nutra Pharma Corp | Company report | 85% |
| Denali Therapeutics Inc | Company report | 85% |
| Alpha Cognition Inc. | Company report | 85% |
| Tourmaline Bio Inc | Company report | 85% |
| Fibrobiologics Inc | Company report | 85% |
| Promis Neurosciences inc | Company report | 85% |
| MNMD | Company report | 85% |
| Definium Therapeutics Inc | Company report | 85% |
| Neurosense Therapeutics Ltd | Company report | 85% |
| Damora Therapeutics Inc | Company report | 85% |
| SAVA | Company report | 85% |
| Vaxxinity Inc | Company report | 85% |
| Centessa Pharmaceuticals Plc | Company report | 85% |
| GLTO | Company report | 85% |
| Pliant Therapeutics Inc | Company report | 85% |
| Scholar Rock Holding Corp | Company report | 85% |
| Alector Inc | Company report | 85% |
| Anavex Life Sciences Corp | Company report | 85% |
| Ovid Therapeutics Inc | Company report | 85% |
| 4d Molecular Therapeutics Inc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Biovie Inc | Company report | 85% |
| Uniqure N v | Company report | 85% |
| Alzamend Neuro Inc | Company report | 85% |
| Range Impact Inc | Company report | 85% |
| Amylyx Pharmaceuticals Inc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Zynerba Pharmaceuticals Inc | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Sanofi | Company report | 85% |
| Ptc Therapeutics inc | Company report | 85% |
| Exelixis Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Argenx Se | Company report | 85% |
| Sage Therapeutics Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Cerevel Therapeutics Holdings Inc | Company report | 85% |
| Sarepta Therapeutics Inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Ultragenyx Pharmaceutical Inc | Company report | 85% |
| Seagen Inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Biogen Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Biogen Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Biogen Inc | Reportable 100.00 % |
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Biogen Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Biogen Inc | 36,706 | 1,372,973 | 46,333 |
| Eli Lilly And Company | 1,209,664 | 1,729,240 | 551,594 |
| Johnson and Johnson | 676,352 | 705,504 | 114,311 |
| Abbvie Inc | 516,201 | 1,158,140 | 181,509 |
| Merck and Co Inc | 362,398 | 887,587 | 42,267 |
| Novartis Ag | 317,785 | 752,973 | 185,566 |
| PEERS TOTAL | 4,661,052 | 980,082 | 139,705 |
Biogen Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
| Abbott Laboratories | Non-US 57.70 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Biogen Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 158 companies in Biogen Inc's industry classification, broader than the peer set above. Market cap in millions of $.Biogen Inc ranks #6 of 158 companies by market capitalization in its industry, holding 3.84 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,353, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 250,468 | 26.02 % |
| 2 | Gilead Sciences Inc | 207,444 | 21.55 % |
| 3 | Moderna Inc | 101,168 | 10.51 % |
| 4 | Argenx Se | 61,223 | 6.36 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 36,930 | 3.84 % |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Mesoblast Limited | 1,234 | 5.2% |
| 9 | Exelixis Inc | 1,234 | 5.2% |
| 10 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
Market cap and industry share for the rest of Biogen Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Biogen Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 1 | Amgen Inc | 250,468 | 41.60 % |
| 2 | Gilead Sciences Inc | 207,444 | 35.22 % |
| 3 | Moderna Inc | 101,168 | 950.64 % |
| 4 | Argenx Se | 61,223 | 8.23 % |
| 5 | Revolution Medicines Inc | 1,234 | 12.3% |
| 6 | Biogen Inc | 36,930 | 59.15 % |
| 7 | Biontech Se | 1,234 | 12.3% |
| 8 | Mesoblast Limited | 1,234 | 12.3% |
| 9 | Exelixis Inc | 1,234 | 12.3% |
| 10 | Neurocrine Biosciences Inc | 1,234 | 12.3% |
| 11 | Kymera Therapeutics Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Biogen Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Biogen Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (160 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 54.93 % | 34.84 % (avg) | +20.1 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | 19.18 % | -2.62 % (avg) | +21.8 pp |
| Capital Intensity (Capex / Revenue) | 1.87 % | 8.89 % (avg) | -7.0 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Biogen Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (160 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 90.6x | 27.3x | +63.2x |
| EV / EBITDA | 19.3x | 17.0x | +2.3x |
| P/B | 1.7x | 5.1x | -3.4x |
| Return on Equity | 1.86 % | industry aggregate | 7.93 % |
| Return on Invested Capital | - | -11.80 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Biogen Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 9.61 % | 6.88 % | -6.49 % | -18.32 % | -7.36 % | -3.32 % | -1.62 % | 2.22 % |
| Operating Margin | 43.77 % | 48.98 % | 33.84 % | 25.87 % | 34.24 % | 18.62 % | 25.88 % | 22.30 % |
| Return on Invested Capital | 16.69 % | 19.31 % | 13.79 % | 8.94 % | 10.52 % | 4.91 % | 6.34 % | 5.12 % |
| P/E | 14.8x | 9.3x | 10.4x | 23.3x | 13.7x | 30.7x | 15.1x | 18.5x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Biogen Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Biogen Inc falls in the Dog quadrant: relative market share of 0.15x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Biogen Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,353 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.87 % vs industry average 8.89 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Biogen Inc's dedicated Suppliers and Customers pages, not here.
Biogen Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Biogen Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Biogen Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 7.9 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+8.9% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Low relative market share vs the industry leader (0.15x).
Opportunities
- A meaningful share of competitors (53.20 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Biogen Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Biogen Inc | 0.08 | 2.33 | 0.38 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Biogen Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Biogen Inc | Q3 2026 | +10.6 % | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| PEERS TOTAL | +12.8 % | -4.7 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Biogen Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Biogen Inc | Q3 2026 | +11.0 % | -21.6 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
Biogen Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Biogen Inc | 1.13% | 1.26% | 1.86% |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Biogen Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Biogen Inc | 106.05 | 3.56 |
| Eli Lilly And Company | 43.96 | 13.99 |
| Johnson and Johnson | 41.79 | 6.81 |
| Abbvie Inc | 50.14 | 7.82 |
| Merck and Co Inc | 118.32 | 5.44 |
| Novartis Ag | 22.73 | 5.61 |
| PEERS AVERAGE | 45.04 | 6.35 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.